| Identification | Back Directory | [Name]
Ethanesulfonamide, N-[5-(4-chlorophenyl)-3,4-dihydroxy-2-furanyl]- | [CAS]
1585219-04-0 | [Synonyms]
FTO-IN-7d
Ethanesulfonamide, N-[5-(4-chlorophenyl)-3,4-dihydroxy-2-furanyl]- | [Molecular Formula]
C12H12ClNO5S | [MOL File]
1585219-04-0.mol | [Molecular Weight]
317.75 |
| Chemical Properties | Back Directory | [Boiling point ]
474.0±55.0 °C(Predicted) | [density ]
1.562±0.06 g/cm3(Predicted) | [solubility ]
DMSO:31.77(Max Conc. mg/mL);100.0(Max Conc. mM) | [form ]
Solid | [pka]
7.68±0.50(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Description]
MO-I-500 is a FTO inhibitor (IC50 = 8.7 μM for purified FTO in vitro), which increases N6-methyladenosine (m6A) levels in total cellular mRNA in HeLa cells. MO-I-500 modulates levels of specific miRNAs. In a triple-negative breast cancer cell line metabolically challenged by culture without glutamine (SUM149-MA cells), MO-I-500 inhibits cell proliferation. MO-I-500 also displays anticonvulsant activity in a 6 Hz mouse model of epilepsy at nontoxic doses. | [Uses]
MO-I-500 is a pharmacological of FTO inhibitor with an IC50 of 8.7 μM for the inhibition of purified FTO demethylase catalyzing demethylation of an artificial small methylated substrate. MO-I-500 can be used for the research of rare panresistant triple-negative inflammatory breast cancer[1]. | [storage]
Store at -20°C | [References]
[1] Balraj Singh et al. Important Role of FTO in the Survival of Rare Panresistant Triple-Negative Inflammatory Breast Cancer Cells Facing a Severe Metabolic Challenge. PLoS One. 2016 Jul 8;11(7):e0159072. DOI:10.1371/journal.pone.0159072 |
|
| Company Name: |
R&D Systems, Inc
|
| Tel: |
18003437475 18003437475 |
| Website: |
www.rndsystems.com |
|